Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $2 | $12 | $9 | $39 |
| - Cash | $1 | $4 | $14 | $21 |
| + Debt | $1 | $10 | $1 | $10 |
| Enterprise Value | $2 | $18 | -$4 | $28 |
| Revenue | $8 | $2 | $3 | $9 |
| % Growth | 404.2% | -51.6% | -63.9% | – |
| Gross Profit | $5 | $1 | $0 | $4 |
| % Margin | 63.2% | 36.8% | 10.1% | 40.4% |
| EBITDA | -$7 | -$11 | -$23 | -$37 |
| % Margin | -83.3% | -723.6% | -694.4% | -404.3% |
| Net Income | -$7 | -$12 | -$24 | -$37 |
| % Margin | -89.1% | -776.7% | -721.6% | -410.7% |
| EPS Diluted | -13.83 | -1.59 | -5.03 | -19.64 |
| % Growth | -769.8% | 68.4% | 74.4% | – |
| Operating Cash Flow | -$4 | -$10 | -$23 | -$29 |
| Capital Expenditures | $0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$4 | -$11 | -$23 | -$31 |